{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:15:37Z","timestamp":1791900937154,"version":"4.3.4"},"reference-count":99,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2020,1,22]]},"DOI":"10.3233\/jnd-190424","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T13:41:11Z","timestamp":1573220471000},"page":"1-13","source":"Crossref","is-referenced-by-count":218,"title":["Advances in Treatment of Spinal Muscular Atrophy \u2013 New Phenotypes, New Challenges, New Implications for Care"],"prefix":"10.1177","volume":"7","author":[{"given":"David C.","family":"Schorling","sequence":"first","affiliation":[{"name":"Department of Neuropediatrics and Muscle Disorders, Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Pechmann","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics and Muscle Disorders, Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[{"name":"Department of Neuropediatrics and Muscle Disorders, Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"},{"name":"Department of Neuropediatrics, University Hospital Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JND-190424_ref1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/archneur.1971.00490030102014","article-title":"Two early infantile hereditary cases of progressive muscular atrophy simulating dystrophy, but on a neural basis. 1891","volume":"25","author":"Werdnig","year":"1971","journal-title":"Arch Neurol"},{"key":"10.3233\/JND-190424_ref2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/BF01668496","article-title":"Ueber chronische spinale Muskelatrophie im Kindesalter, auf famili\u00e4rer Basis","volume":"3","author":"Hoffmann","year":"1893","journal-title":"Dtsch Z F\u00fcr Nervenheilkd"},{"key":"10.3233\/JND-190424_ref3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/344540a0","article-title":"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"key":"10.3233\/JND-190424_ref4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/344767a0","article-title":"Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q","volume":"344","author":"Melki","year":"1990","journal-title":"Nature"},{"key":"10.3233\/JND-190424_ref5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.3233\/JND-190424_ref6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ajmg.10425","article-title":"Genetic risk assessment in carrier testing for spinal muscular atrophy","volume":"110","author":"Ogino","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.3233\/JND-190424_ref7","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet Lond Engl"},{"key":"10.3233\/JND-190424_ref8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy \u2013 a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.3233\/JND-190424_ref9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13023-019-1125-2","article-title":"De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in Germany","volume":"14","author":"K\u00f6nig","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.3233\/JND-190424_ref10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0960-8966(91)90052-T","article-title":"International SMA Collaboration","volume":"1","author":"Munsat","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.3233\/JND-190424_ref11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch Neurol"},{"key":"10.3233\/JND-190424_ref12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","author":"Farrar","year":"2013","journal-title":"J Pediatr"},{"key":"10.3233\/JND-190424_ref13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","article-title":"A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients","volume":"146","author":"Zerres","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.3233\/JND-190424_ref14","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/4.10.1927","article-title":"Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: Evidence of homozygous deletions of the SMN gene in unaffected individuals","volume":"4","author":"Hahnen","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JND-190424_ref15","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/brain\/awu169","article-title":"Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies","volume":"137","author":"Peeters","year":"2014","journal-title":"Brain J Neurol"},{"key":"10.3233\/JND-190424_ref16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number","volume":"119","author":"Wirth","year":"2006","journal-title":"Hum Genet"},{"key":"10.3233\/JND-190424_ref17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord NMD"},{"key":"10.3233\/JND-190424_ref18","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JND-190424_ref19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.3233\/JND-190424_ref20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases","volume":"3","author":"Butchbach","year":"2016","journal-title":"Front Mol Biosci"},{"key":"10.3233\/JND-190424_ref21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ajmg.a.30251","article-title":"Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2","volume":"130A","author":"Prior","year":"2004","journal-title":"Am J Med Genet A"},{"key":"10.3233\/JND-190424_ref22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10.3233\/JND-190424_ref23","doi-asserted-by":"publisher","first-page":"e0213680","DOI":"10.1371\/journal.pone.0213680","article-title":"Systemic nature of spinal muscular atrophy revealed by studying insurance claims","volume":"14","author":"Lipnick","year":"2019","journal-title":"PloS One"},{"key":"10.3233\/JND-190424_ref24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.3233\/JND-190424_ref25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00415-013-7154-1","article-title":"Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe","volume":"261","author":"Bladen","year":"2014","journal-title":"J Neurol"},{"key":"10.3233\/JND-190424_ref26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord NMD"},{"key":"10.3233\/JND-190424_ref27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute caremedications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord NMD"},{"key":"10.3233\/JND-190424_ref28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/mus.25776","article-title":"Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I","volume":"57","author":"Krosschell","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.3233\/JND-190424_ref29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/mus.23904","article-title":"SMA valiant trial: A prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy","volume":"49","author":"Kissel","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.3233\/JND-190424_ref30","doi-asserted-by":"publisher","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"Kissel","year":"2011","journal-title":"PloS One"},{"key":"10.3233\/JND-190424_ref31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy","volume":"68","author":"Mercuri","year":"2007","journal-title":"Neurology"},{"key":"10.3233\/JND-190424_ref32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot trial of albuterol in spinal muscular atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology"},{"key":"10.3233\/JND-190424_ref33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00002060-200009000-00005","article-title":"A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report","volume":"79","author":"Tzeng","year":"2000","journal-title":"Am J Phys Med Rehabil"},{"key":"10.3233\/JND-190424_ref34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nmd.2013.10.011","article-title":"Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study","volume":"24","author":"Kirschner","year":"2014","journal-title":"Neuromuscul Disord NMD"},{"key":"10.3233\/JND-190424_ref35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study","volume":"18","author":"Merlini","year":"2003","journal-title":"J Child Neurol"},{"key":"10.3233\/JND-190424_ref36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"Miller","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.3233\/JND-190424_ref37","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/archneur.60.11.1601","article-title":"A phase 1 trial of riluzole in spinal muscular atrophy","volume":"60","author":"Russman","year":"2003","journal-title":"Arch Neurol"},{"key":"10.3233\/JND-190424_ref38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Bertini","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JND-190424_ref39","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.3233\/JND-190424_ref40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1083\/jcb.201207087","article-title":"Antisense-based therapy for the treatment of spinal muscular atrophy","volume":"199","author":"Rigo","year":"2012","journal-title":"J Cell Biol"},{"key":"10.3233\/JND-190424_ref41","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.3233\/JND-190424_ref42","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JND-190424_ref43","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.3233\/JND-190424_ref44","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.3233\/JND-190424_ref45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/JND-190424_ref46","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/j.ejpn.2017.04.1218","article-title":"Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): Interim results from the NURTURE study","volume":"21","author":"Bertini","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"10.3233\/JND-190424_ref47","doi-asserted-by":"crossref","unstructured":"De Vivo DC , Bertini E , Swoboda KJ , Wuh-Liang H , Crawford TO , Finkel R , et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019; accepted.","DOI":"10.1212\/WNL.92.15_supplement.S25.001"},{"key":"10.3233\/JND-190424_ref48","doi-asserted-by":"publisher","first-page":"e00447","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.3233\/JND-190424_ref50","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1517\/14712598.2012.681463","article-title":"The advent of AAV9 expands applications for brain and spinal cord gene delivery","volume":"12","author":"Dayton","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.3233\/JND-190424_ref51","doi-asserted-by":"publisher","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.3233\/JND-190424_ref52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.3233\/JND-190424_ref53","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.3233\/JND-190424_ref54","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190403"},{"key":"10.3233\/JND-190424_ref55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/14712598.2018.1416089","article-title":"AAV gene delivery to the spinal cord: Serotypes, methods, candidate diseases, and clinical trials","volume":"18","author":"Hardcastle","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.3233\/JND-190424_ref56","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/gt.2011.130","article-title":"Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs","volume":"19","author":"Federici","year":"2012","journal-title":"Gene Ther"},{"key":"10.3233\/JND-190424_ref57","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1089\/hum.2011.008","article-title":"Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery","volume":"22","author":"Snyder","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.3233\/JND-190424_ref58","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","article-title":"Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy","volume":"28","author":"Long","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JND-190424_ref59","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/mus.26017","article-title":"CK-2127107 amplifies skeletal muscle response to nerve activation in humans","volume":"57","author":"Andrews","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.3233\/JND-190424_ref60","doi-asserted-by":"publisher","first-page":"e0166803","DOI":"10.1371\/journal.pone.0166803","article-title":"Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy","volume":"11","author":"Liu","year":"2016","journal-title":"PloS One"},{"key":"10.3233\/JND-190424_ref61","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1016\/j.celre2017.12.003","article-title":"Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Atrophy","volume":"21","author":"Simon","year":"2017","journal-title":"Cell Rep"},{"key":"10.3233\/JND-190424_ref62","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3389\/fneur.2019.00898","article-title":"Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy","volume":"10","author":"Kariyawasam","year":"2019","journal-title":"Front Neurol"},{"key":"10.3233\/JND-190424_ref63","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JND-190424_ref64","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and Treatment effects of Nusinersen in longstanding adult 5q-SMA type 3 \u2013 a prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.3233\/JND-190424_ref65","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"key":"10.3233\/JND-190424_ref66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2015.06.002","article-title":"Delay in Diagnosis of Spinal Muscular Atrophy: A Systematic Literature Review","volume":"53","author":"Lin","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.3233\/JND-190424_ref67","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/gim.2017.152","article-title":"Pilot study of population-based newborn screening for spinal muscular atrophy in New York state","volume":"20","author":"Kraszewski","year":"2018","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10.3233\/JND-190424_ref68","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.nmd.2019.02.003","article-title":"Newborn screening for SMA in Southern Belgium","volume":"29","author":"Boemer","year":"2019","journal-title":"Neuromuscul Disord NMD"},{"key":"10.3233\/JND-190424_ref69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JND-190428","article-title":"One year of newborn screening for SMA \u2013 Results of a German pilot project","volume":"6","author":"Vill","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.3233\/JND-190424_ref70","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening","volume":"190","author":"Chien","year":"2017","journal-title":"J Pediatr"},{"key":"10.3233\/JND-190424_ref71","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1373\/clinchem.2014.231019","article-title":"Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency","volume":"61","author":"Taylor","year":"2015","journal-title":"Clin Chem"},{"key":"10.3233\/JND-190424_ref72","unstructured":"Gutierez-Mateo C , Baker M , Mochal S , Moore K , Filippov G , Dallaire S . A five-plex qPCR assay that measures copy numbers of SMN1, SMN2, TREC, KREC and RPP30. Am. Coll. Med. Genet. Genomics, vol. March 21-25, Phoenix, AZ: 2017."},{"key":"10.3233\/JND-190424_ref73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/acn3.689","article-title":"Novel challenges in spinal muscular atrophy \u2013 How to screen and whom to treat?","volume":"6","author":"Saffari","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JND-190424_ref74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.3233\/JND-190424_ref75","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.gde.2013.03.003","article-title":"How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches","volume":"23","author":"Wirth","year":"2013","journal-title":"Curr Opin Genet Dev"},{"key":"10.3233\/JND-190424_ref76","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/gim.2017.134","article-title":"Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy in Australia: outcomes of 12,000 tests","volume":"20","author":"Archibald","year":"2018","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10.3233\/JND-190424_ref77","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1055\/s-0036-1593347","article-title":"Prenatal Carrier Screening for Spinal Muscular Atrophy","volume":"33","author":"Wood","year":"2016","journal-title":"Am J Perinatol"},{"key":"10.3233\/JND-190424_ref78","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/jmg.2008.057950","article-title":"Congenital heart disease is a feature of severe infantile spinal muscular atrophy","volume":"45","author":"Rudnik-Sch\u00f6neborn","year":"2008","journal-title":"J Med Genet"},{"key":"10.3233\/JND-190424_ref79","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/PHM.0b013e31804b1d66","article-title":"Medical considerations of long-term survival of Werdnig-Hoffmann disease","volume":"86","author":"Bach","year":"2007","journal-title":"Am J Phys Med Rehabil"},{"key":"10.3233\/JND-190424_ref80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0887-8994(94)00100-g","article-title":"Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)?","volume":"12","author":"Tein","year":"1995","journal-title":"Pediatr Neurol"},{"key":"10.3233\/JND-190424_ref81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/1531-8249(199903)45:3<337::AID-ANA9>3.0.CO;2-U","article-title":"Abnormal fatty acid metabolism in childhood spinal muscular atrophy","volume":"45","author":"Crawford","year":"1999","journal-title":"Ann Neurol"},{"key":"10.3233\/JND-190424_ref82","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/bmme.1997.2590","article-title":"Expression study of survival motor neuron gene in human fetal tissues","volume":"61","author":"Novelli","year":"1997","journal-title":"Biochem Mol Med"},{"key":"10.3233\/JND-190424_ref83","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.nmd.2017.09.006","article-title":"Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience","volume":"27","author":"Messina","year":"2017","journal-title":"Neuromuscul Disord NMD"},{"key":"10.3233\/JND-190424_ref84","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.3233\/JND-190424_ref85","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","article-title":"Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function","volume":"28","author":"Pane","year":"2018","journal-title":"Neuromuscul Disord NMD"},{"key":"10.3233\/JND-190424_ref86","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: expanded access programme","volume":"89","author":"Farrar","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JND-190424_ref87","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JND-190424_ref88","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00115-018-0653-7","article-title":"[Treatment evaluation in patients with 5q-associated spinal muscular atrophy: Real-world experience]","volume":"90","author":"Walter","year":"2019","journal-title":"Nervenarzt"},{"key":"10.3233\/JND-190424_ref91","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","article-title":"SMArtCARE \u2013 A platform to collect real-life outcome data of patients with spinal muscular atrophy","volume":"14","author":"Pechmann","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.3233\/JND-190424_ref92","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3233\/JND-180325","article-title":"Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients","volume":"5","author":"Lochm\u00fcller","journal-title":"J Neuromuscul Dis"},{"key":"10.3233\/JND-190424_ref93","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/BPO.0b013e31821722b1","article-title":"Early treatment of scoliosis with growing rods in children with severe spinal muscular atrophy: a preliminary report","volume":"31","author":"Chandran","year":"2011","journal-title":"J Pediatr Orthop"},{"key":"10.3233\/JND-190424_ref94","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/BPO.0000000000000867","article-title":"Radiographic and Respiratory Effects of Growing Rods in Children With Spinal Muscular Atrophy","volume":"37","author":"Lenhart","year":"2017","journal-title":"J Pediatr Orthope"},{"key":"10.3233\/JND-190424_ref95","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418803246","article-title":"Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy","volume":"11","author":"Stolte","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.3233\/JND-190424_ref96","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00415-018-9124-0","article-title":"Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients","volume":"266","author":"Wurster","year":"2019","journal-title":"J Neurol"},{"key":"10.3233\/JND-190424_ref97","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00234-019-02189-x","article-title":"Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy","volume":"61","author":"Oldenburg","year":"2019","journal-title":"Neuroradiology"},{"key":"10.3233\/JND-190424_ref98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2019.2.SPINE181366","article-title":"Lumbar laminotomy for the intrathecal administration of nusinersen for spinal muscular atrophy: technical note and outcomes","author":"Ko","year":"2019","journal-title":"J Neurosurg Spine"},{"key":"10.3233\/JND-190424_ref99","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/BPO.0000000000001247","article-title":"Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy","volume":"38","author":"Strauss","year":"2018","journal-title":"J Pediatr Orthope"},{"key":"10.3233\/JND-190424_ref100","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1212\/WNL.0000000000006006","article-title":"Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy","volume":"91","author":"Veerapandiyan","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JND-190424_ref101","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol"},{"key":"10.3233\/JND-190424_ref102","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-0037-1603517","article-title":"Diagnosis and New Treatment Avenues in Spinal Muscular Atrophy","volume":"48","author":"Pechmann","year":"2017","journal-title":"Neuropediatrics"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-190424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:24Z","timestamp":1777506564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-190424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":99,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jnd-190424","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]}}}